PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
PTC Therapeutics (PTCT) Misses Q1 EPS by 40c, Beats on Revenue
April 27, 2023 4:07 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.88), $0.40 worse than the analyst estimate of ($1.48). Revenue for the quarter came in at $220.4 million versus the consensus estimate of $205.47 million.
GUIDANCE:
PTC Therapeutics sees FY2023 revenue of $0.94-1 billion vs $0.87 billion... More



